Article
3m Read
November 19, 2024
ANTIMICROBIAL STEWARDSHIP
Impact Story
3m Read
September 12, 2024
ANTIMICROBIAL STEWARDSHIP
Main Menu
-
Solutions
Back
Cepheid’s Solutions
-
Global Access
-
Antibiotic Stewardship
-
Customized Menu and Scalability
-
Testing Everywhere
Back
Testing Everywhere
-
Knowing MORE Matters
-
Workflow and Connectivity
-
-
Insights
Back
Cepheid’s Insights
-
Webinars
-
Cepheid RADAR
Back
Cepheid RADAR
-
Support
Back
Support Center
-
Documents & Technical Resources
-
Troubleshooting and How-tos
-
MyCepheid and Order Support
-
Reimbursement Guidelines
-
Contact Us
Back
Contact Us
-
-
About Us
Back
About Cepheid
-
Mission and History
Back
Mission and History
-
Our Leadership
Back
Our Leadership
-
Events
Back
Events
-
Sustainability
-
Reimbursement Support
-
Distributors
Back
Distributors
-
Government Partnerships
-
Business Development Opportunities
-
Innovate with Cepheid
-
Meet the Cepheid Bike
-
News
Back
News
-
The Need
- Vancomycin Resistant Enterococci (VRE) are a growing public health threat and pose a risk to patient safety in healthcare facilities1
- In healthcare settings, colonized patients and environmental contamination contribute to VRE spread1
- High-risk patients colonized with VRE have 24 times increased infection risk2
- Infections caused by VRE are associated with high mortality3
- VRE has an impact on patient length-of-stay, and in turn, hospitalization costs3
1 Levitus M, et al. Vancomycin-Resistant Enterococci. StatPearls July 17, 2023. https://www.ncbi.nlm.nih.gov/books/NBK513233/?report=reader#_NBK513233_pubdet. Accessed December 11, 2023
2 Alevizakos M, et al. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016 Dec;4(1):ofw246.
3 Eichel V,M, et al. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis. Journal of Hospital Infection 141 (2023) 119e128
2 Alevizakos M, et al. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016 Dec;4(1):ofw246.
3 Eichel V,M, et al. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis. Journal of Hospital Infection 141 (2023) 119e128
The Solution
- The Xpert vanA test is a rapid molecular detection of the vanA gene associated with VRE colonization risk to aid in the recognition, prevention, and control of vancomycin-resistant organisms that colonize patients in healthcare settings
- Fast, active screening of high-risk patients to support infection control measures in healthcare settings4
4 Babady N,E, et al. Performance Characteristics of the Cepheid Xpert vanA Assay for Rapid Identification of Patients at High Risk for Carriage of Vancomycin-Resistant Enterococci. Journal of Clinical Microbiology, November 2012 Volume 50 Number 11 p. 3659–3663
The Impact
Published studies have reported improved infection control workflows following implementation of rapid molecular screening5
- 93% reduction of turnaround time from 70.5h with chromogenic agar culture to 4.6h
- High negative predictive value allows for better management of non-colonized patients
- Associated with a reduction in the number of identified contact patients
- 141 saved isolation days and 292 saved transmission risk days
5 Birgand G, et al. Lucet JC. Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. Antimicrobial Resistant and Infection Control. 2013 Nov 2:30.
6 Holzknecht BJ, Hansen DS, Nielsen L, Kailow A, Jarløv JO. Screening for vancomycin-resistant enterococci with Xpert® vanA/vanB: diagnostic accuracy and impact on infection control decision making. New Microbes New Infect. 2017 Jan 12;16:54-59
* 1€=1.09$, conversion rate December 15th 2023
6 Holzknecht BJ, Hansen DS, Nielsen L, Kailow A, Jarløv JO. Screening for vancomycin-resistant enterococci with Xpert® vanA/vanB: diagnostic accuracy and impact on infection control decision making. New Microbes New Infect. 2017 Jan 12;16:54-59
* 1€=1.09$, conversion rate December 15th 2023